Company Profile

HybridStat is an SME located in Athens, Greece, bringing together a team of highly qualified and motivated young scientists, whose expertise spans a variety of biology, statistics and computer science domains. HybridStat’s services are centered on bioinformatics and analytics of high-throughput biological data derived from technologies such as Next Generation Sequencing and mass spectrometry. In addition, HybridStat develops software and database solutions to tackle the challenges presented by big biological data, based on modern cloud computing technologies.

Furthermore, the team has a strong background on information personalization and recommendation technologies which will be exploited towards building complete bioinformatics solutions/suites, specific for the needs of research and diagnostics laboratories as well as related biotech companies with interest in developing personalized medicine solutions.

The team members have participated in several research projects (EU and national) where bioinformatics analysis and the development of new analysis techniques, algorithms and software had a crucial role, and a major part of HybridStat’s current collaborations/projects is centered on bioinformatics. In addition, HybridStat has received equity free funding from two EU accelerators (Finodex, Odine) for the development of its innovative products and services.

Last but not least, HybridStat aims to mitigate the resource waste for diagnostic labs required to acquire, analyze and interpret the data as well as the cost (time and money) for diagnostic labs to reach diagnostic conclusions, thus increasing their throughput. In addition, HybridStat’s goals include the automation and standardization of data analysis procedure for diagnostic labs and hospitals, allowing their customers to offer fast and reliable services by using HybridStat’s products and services.

Target Partners & Collaborations

HybridStat seeks collaborations in Greece and abroad with:

  • Diagnostic labs and hospitals who already apply or seek to explore and incorporate Next Generation Sequencing approaches (Whole Exome, Whole Genome or Targeted Sequencing) into their routinely diagnostic pipelines.
  • Pharma companies who apply Next Generation Sequencing routinely for research and drug development as well as the derivation of precision and personalized medicine approaches.
  • Research institutions and universities, for collaborative research and education purposes as well as addressing advanced bioinformatics requirements for scientific projects.
  • Next Generation Sequencing facilities interested in providing complete, integrative and scalable bioinformatics solutions to their customers.

Technologies / Services offered or sought

HybridStat offers Geniasis™ (https://geniasis.com), a cloud-based medical decision support system which is based on the analysis of modern clinical Next Generation Sequencing data. Geniasis supports accurate diagnostics towards the derivation of personalized medical treatment plans by exploiting open source algorithms and open scientific data coupled with proprietary optimized analysis workflows and data annotation systems which provide accurate filtered results of unprecedented accuracy. In this way, clinical geneticists and biologists are able to reach timely conclusions and diagnoses.

In addition HybridStat develops SeqCVIBE, a Shiny web application for the interactive data exploration, analysis, visualization and genome browsing of Big RNA-Seq datasets for research purposes. SeqCVIBE allows for several on-the-fly visualizations and calculations, such as averaging genomic tracks over specific regions and calculating RNA abundance in custom possibly non-annotated regions. In addition, SeqCVIBE is at the same time a database for pre-analysed data where the user can navigate and explore the results as well as perform basic analyses on-the-fly in various ways.

Furthermore, HybridStat offers consulting and analytics services, in order to answer medical or biological questions requiring biostatistical and bioinformatics analyses. Specifically, HybridStat offers high-throughput biological data analysis for research and clinical applications in the following domains:


  • Next Generation Sequencing
    • RNA-Seq, ChIP-Seq, Whole Exome and Genome Sequencing, X-Seq* complete data analysis (from raw short sequences to biologically comprehensive results)
    • De novo genome/transcriptome assembly
  • Microarrays
    • DNA and Genotype array data analysis and reporting
  • Data mining and pattern discovery in high throughput genomics data (clusters, motifs, networks)
  • Analysis of gene regulatory regions and elements
  • Functional enrichment analysis (Gene Ontology, Biochemical pathways)


  • Mass spectrometry
    • MS data preprocessing, normalization, peak detection and sample clustering for several high-throughput metabolomics technologies, such as LC-MS(/MS), CE-MS, SELDI/MALDI-TOF MS
    • Identification of metabolite abundance and their quantification
    • Database search, chemical formula inference

You can download HybridStat’s flyer describing briefly products and services here: 

Clients & Collaborations (NATIONAL)

HybridStat has developed several collaborations with academic as well as business partners at a national and European level. Specifically, current collaborations include:

  • Groups from the Biomedical Research Foundation of the Academy of Athens (BRFAA)
  • Groups from the National and Kapodistrian  University of Athens (UoA)
  • The U1048 Unit of the Institut national de la santé et de la recherche médicale (Inserm), Toulouse, France
  • The University of Aveiro, Portugal
  • Genomedica, S.A., Piraeus, Greece
  • DNA Nutricoach, Barcelona, Spain

The aforementioned collaborations include both the provision of services as well as joint R&D activities.

Postal Address
Aiolou 19C
10551 Athens